Published in Gene Therapy Weekly, December 28th, 2006
Gen-Probe's PCA3 gene-based test detects the overexpression of PCA3 mRNA in urine. Studies have shown that, in greater than 95% of prostate cancer cases, PCA3 is 60 to 100-fold over-expressed in prostate cancer cells compared to normal cells, indicating that PCA3 may be a useful biomarker for prostate cancer.
Preliminary data show that the PCA3 assay is more specific to prostate cancer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.